Cholecalciferol supplementation to improve the hepatitis B vaccination response in hemodialysis patients: A first randomized open label pilot study (DeVitaHep)

Vaccine ◽  
2021 ◽  
Author(s):  
Hildegard Hafner-Giessauf ◽  
Sabine Horn ◽  
Gerold Schwantzer ◽  
Hannelore Sprenger-Mähr ◽  
Karl Lhotta ◽  
...  
2017 ◽  
Vol 32 (suppl_3) ◽  
pp. iii681-iii681
Author(s):  
Hildegard Hafner-Giessauf ◽  
Sabine Horn ◽  
Hannelore Sprenger-Maehr ◽  
Kathrin Eller ◽  
Alexander Rosenkranz ◽  
...  

2021 ◽  
pp. 1-8
Author(s):  
Maggie Han ◽  
Xiaoling Ye ◽  
Sharon Rao ◽  
Schantel Williams ◽  
Stephan Thijssen ◽  
...  

<b><i>Background/Aims:</i></b> Hepatitis B (HB) vaccination in hemodialysis patients is important as they are at a higher risk of contracting HB. However, hemodialysis patients have a lower HB seroconversion rate than their healthy counterparts. As better sleep has been associated with better seroconversion in healthy populations and early hemodialysis start has been linked to significant sleep-wake disturbances in hemodialysis patients, we examined if hemodialysis treatment start time is associated with HB vaccination response. <b><i>Methods:</i></b> Demographics, standard-of-care clinical, laboratory, and treatment parameters, dialysis shift data, HB antigen status, HB vaccination status, and HB titers were collected from hemodialysis patients in Fresenius clinics from January 2010 to December 2015. Patients in our analysis received 90% of dialysis treatments either before or after 8:30 a.m., were negative for HB antigen, and received a complete series of HB vaccination (Engerix B® or Recombivax HB™). Univariate and multivariate regression models examined whether dialysis start time is a predictor of HB vaccination response. <b><i>Results:</i></b> Patients were 65 years old, 57% male, and had a HD vintage of 10 months. Patients whose dialysis treatments started before 8:30 a.m. were more likely to be younger, male, and have a greater dialysis vintage. Patients receiving Engerix B® and starting dialysis before 8:30 a.m. had a significantly higher seroconversion rate compared to patients who started dialysis after 8:30 a.m. Early dialysis start was a significant predictor of seroconversion in univariate and multivariate regression including male gender, but not in multivariate regression including age, neutrophil-to-lymphocyte ratio, and vintage. <b><i>Conclusion:</i></b> While better sleep following vaccination is associated with seroconversion in the general population, this is not the case in hemodialysis patients after multivariate adjustment. In the context of end-stage kidney disease, early dialysis start is not a significant predictor of HB vaccination response. The association between objectively measured postvaccination sleep duration and seroconversion rate should be investigated.


Nephron ◽  
2000 ◽  
Vol 84 (3) ◽  
pp. 291-292 ◽  
Author(s):  
M. Deniz Ayli ◽  
Cüneyt Ensari ◽  
Meltem Ayli ◽  
Fahri Mandiroglu ◽  
Suat Mut

2006 ◽  
Vol 10 ◽  
pp. S43
Author(s):  
M. Zubkin ◽  
E. Balakirev ◽  
V. Chervinko ◽  
F. Baranova ◽  
V. Taranov ◽  
...  

2010 ◽  
Vol 2010 ◽  
pp. 1-7 ◽  
Author(s):  
Felix Omeñaca ◽  
Jose Garcia-Sicilia ◽  
Reyes Boceta ◽  
Pilar García-Corbeira

A range of schedules are recommended for hepatitis B vaccination of premature infants. This open-label study (217744/083) compared the immune response of premature (N=94) and full-term infants (N=92) to hepatitis B antigen following primary administration of hexavalent DTPa-HBV-IPV/Hib vaccine at 2–4–6 months and a booster dose at 18 months. Anti-HBsAg antibodies were determined before and one month after primary and booster doses. There were no significant differences in postprimary seroprotection rates (anti-HBsAg >10 mIU/mL; preterm 93.4%; full-term 95.2%) or geometric mean concentrations (634 versus 867 mIU/ml), and neither appeared to be related to gestational length or birth weight. Prebooster seroprotection rates were 75 and 80.6%, respectively. Six premature infants did not respond to primary and booster doses. Primary and booster vaccinations with DTPa-HBV-IPV/Hib elicit satisfactory anti-HBsAg responses in preterm infants, which are not influenced by gestational age or birth weight. This schedule and vaccine will greatly facilitate the immunisation of premature infants.


Sign in / Sign up

Export Citation Format

Share Document